High pretreatment neutrophil–lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer

Clinical and Translational Oncology

Volumn 17, Issue 10, 2015, Pages 772-778

  Shao, N ^a   Cai, Q ^a  

^a Tianjin Hospital of ITCWM   (China)

Author keywords

Combined small cell lung cancer; Neutrophil to lymphocyte ratio; Prognosis; Tumor related inflammation

Indexed keywords

ETOPOSIDE; IRINOTECAN; PLATINUM; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PROGRESSION FREE SURVIVAL; SMALL CELL LUNG CANCER; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BLOOD; CANCER STAGING; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; LEUKOCYTE COUNT; LUNG NEOPLASMS; LUNG RESECTION; LYMPHOCYTE; LYMPHOCYTE COUNT; MIDDLE AGED; NEOPLASMS, COMPLEX AND MIXED; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDY; SMALL CELL LUNG CARCINOMA; THROMBOCYTE; THROMBOCYTE COUNT; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; CAMPTOTHECIN; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKOCYTE COUNT; LUNG NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, COMPLEX AND MIXED; NEUTROPHILS; PLATELET COUNT; PLATINUM COMPOUNDS; PNEUMONECTOMY; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA;

EID: 84941942800     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1289-8     Document Type: Article

References (33)

1. Adelstein DJ, Tomashefski JF Jr, Snow NJ, Horrigan TP, Hines JD. Mixed small cell and non-small cell lung cancer. Chest. 1986;89:699–704.
2. Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small-cell and non-small-cell lung cancer. J Clin Oncol. 1989;7:607–12.
3. Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, Sheppard MN, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184–97.
4. Zhang J, Qi HW, Zheng H, Chen M, Zhu J, Xie HK, et al. Etoposide-cisplatin alternating with vinorelbine-cisplatin versus etoposide-cisplatin alone in patients with extensive disease combined with small cell lung cancer. Asian Pac J Cancer Prev. 2014;15:4159–63.
5. Fushimi H, Kikui M, Morino H, Yamamoto S, Tateishi R, Wada A, et al. Histologic changes in small cell lung carcinoma after treatment. Cancer. 1996;77:278–83.
6. Hage R, Elbers JR. Brutel de la Riviere A and van den Bosch JM. Surgery for combined type small cell lung carcinoma. Thorax. 1998;53:450–3.
7. Weng CT, Chu PY, Liu MT, Chen MK. Small cell carcinoma of the head and neck: a single institution’s experience and review of the literature. J Otolaryngol Head Neck Surg. 2008;37:788–93.
8. Wong YN, Jack RH, Mak V, Henrik M, Davies EA. The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970–2004. BMC Cancer. 2009;9:209.
9. Radice PA, Matthews MJ, Ihde DC, Gazdar AF, Carney DN, Bunn PA, et al. The clinical behavior of “mixed” small cell/large cell bronchogenic carcinoma compared to “pure” small cell subtypes. Cancer. 1982;50:2894–902.
10. Babakoohi S, Fu P, Yang M, Linden PA, Dowlati A. Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer. 2013;14:113–9.
11. Cancer Mantovani A. Inflaming metastasis. Nature. 2009;457:36–7.
12. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94:637–41.
13. Li J, Jiang R, Liu WS, Liu Q, Xu M, Feng QS, et al. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One. 2013;8:e83069.
14. Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009;9:155.
15. Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110:435–40.
16. Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 2013;62:471–9.
17. Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013;13:350.
18. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet–lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466–72.
19. Hong S, Kang YA, Cho BC, Kim DJ. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J. 2012;53:111–7.
20. Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014;111:452–60.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
22. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30:432.
23. Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:58.
24. Yuan D, Zhu K, Li K, Yan R, Jia Y, Dang C. The preoperative neutrophil–lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction. J Surg Oncol. 2014;110:333–40.
25. Wang X, Jiang R, Li K. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer. Cell Biochem Biophys. 2014;69:633–40.
26. Xiao GQ, Liu C, Liu DL, Yang JY, Yan LN. Neutrophil–lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation. World J Gastroenterol. 2013;19:8398–407.
27. Lee WS, Park YL, Kim N, Oh HH, Son DJ, Kim MY, et al. Myeloid cell leukemia-1 is associated with tumor progression by inhibiting apoptosis and enhancing angiogenesis in colorectal cancer. Am J Cancer Res. 2015;5:101–13.
28. Wang W, Ma XP, Shi Z, Zhang P, Ding DL, Huang HX, et al. Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma. Am J Cancer Res. 2015;5:396–410.
29. Cullen SJ, Fatemie S, Ladiges W. Breast tumor cells primed by endoplasmic reticulum stress remodel macrophage phenotype. Am J Cancer Res. 2013;3:196–210.
30. Li X, Han Z, Cheng Z, Yu J, Liu S, Yu X, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of recurrence following thermal ablation for recurrent hepatocellular carcinoma: a retrospective analysis. PLoS One. 2014;9:e110546.
31. Dong Y, Richards JA, Gupta R, Aung PP, Emley A, Kluger Y, et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene. 2014;33:4632–42.
32. Nagai S, Abouljoud MS, Kazimi M, Brown KA, Moonka D, Yoshida A. Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation. Transplantation. 2014;97:694–701.
33. Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi99–105.